VFDB - antivirulence drug (3R)-5-Oxo-6-(morpholinomethyl)-7-(1-naphthylmethyl)-8-cyclopropyl-2,3-dihydro-5H-thiazolo[3,2-a]pyridine-3beta-carboxylic acid lithium salt

Acinetobacter

Aeromonas

Anaplasma

Bacillus

Bartonella

Bordetella

Brucella

Burkholderia

Campylobacter

Chlamydia

Clostridium

Corynebacterium

Coxiella

Enterococcus

Escherichia

Francisella

Haemophilus

Helicobacter

Klebsiella

Legionella

Listeria

Mycobacterium

Mycoplasma

Neisseria

Pseudomonas

Rickettsia

Salmonella

Shigella

Staphylococcus

Streptococcus

Vibrio

Yersinia

(3R)-5-Oxo-6-(morpholinomethyl)-7-(1-naphthylmethyl)-8-cyclopropyl-2,3-dihydro-5H-thiazolo[3,2-a]pyridine-3beta-carboxylic acid lithium salt

Drug details:
Molecular formula: C₂₇H₂₇LiN₂O₄S

Standard name: lithium;(3R)-8-cyclopropyl-6-(morpholin-4-ylmethyl)-7-(naphthalen-1-ylmethyl)-5-oxo-2,3-dihydro-[1,3]thiazolo[3,2-a]pyridine-3-carboxylate

Classification: Amino acids, peptides, and analogues; Carboxylic acids and derivatives; Organic acids and derivatives; Organic compounds;

Curated SMILES: [Li+].[O-]C(=O)[C@H]1CSC2=C(C3CC3)C(CC3=CC=CC4=C3C=CC=C4)=C(CN3CCOCC3)C(=O)N21

Chemical structure:

Escherichia
Related VF: Type 1 fimbriae; P fimbriae
Target: PapD
Drug effect: Blocking chaperone and usher functions.
Max phase: In vivo
Publication:
Pinkner JS, et al., 2006. Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria. Proc Natl Acad Sci U S A 103(47):17897-902.


	Back to Top

2004-2024 NIPB, CAMS&PUMC